Article
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all
10 Nov 2019
Abstract excerpt
The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80-90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure for all patients with APL. We review the issue of early death and coagulopathy and discuss the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
